PNT2003, also known as lutetium-177 Octreotate (177Lu-DOTATATE), is a somatostatin-targeted radioligand therapy in development for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors, both GEP-NETs and non-GEP-NETs. It is currently completing its Phase 3 trial.

We licensed worldwide rights to the clinical data and the intellectual property for PNT2003 from CanProbe, a joint venture between CPDC (Centre for Probe Development and Commercialization) and UHN (University Health Network).